Market Access and Health Policy

Helping clients achieve successful commercial launches, optimized pricing and reimbursement, and market access across the MENA region.

Leveraging our in-depth knowledge and relationships with key stakeholders in the MENA region’s most influential healthcare systems, HTAs, and payers, we deliver tailored, action-oriented strategies that navigate the complexities of healthcare systems, optimize pricing and reimbursement outcomes, and drive successful patient access.

Health policy, pricing, reimbursement, and market access strategy

CCHO develops robust strategies that align with MENA-region health policy trends, optimize pricing, and secure favorable reimbursement and market access conditions for our clients’ assets. Our approach integrates thorough market and competitive analysis, stakeholder engagement, and strategic planning to navigate complex regulatory and reimbursement landscapes.

Pricing and market access landscape assessments

Our thorough landscape assessments provide a clear understanding of the market environment, stakeholder needs, and competitive dynamics, enabling informed strategic decisions. The deep and comprehensive insights gathered through primary and secondary research help CCHO identify pricing and market access opportunities, risks, challenges, mitigation strategies, and evidence generation tactics. This holistic view allows our clients to proactively address access and reimbursement barriers and leverage market opportunities to maximize product access.

Across the unmet need, clinical value, economic value, and policy domains, we analyze:

Launch readiness planning

We offer comprehensive launch readiness planning to ensure new products are effectively introduced to the market, meeting regulatory and HTA requirements while achieving rapid uptake. Our services include:

• Pre-launch market preparation
• Cross-functional global-regional team coordination
• Strategic communication and action plans

Managed entry agreements and value-based contracting

We support in educating, designing, and negotiating managed entry agreements and value-based contracts that align incentives across stakeholders, ensuring sustainable access to our clients’ innovative treatments. These agreements help mitigate financial risk and demonstrate the real-world value of novel therapies. Our expertise includes:

• Developing outcome-based pricing models
• Risk-sharing agreements
• Performance metrics to ensure value for payers and patients